Noticias de ARQT_US

Mercado

Noticias del mercado

Últimas noticias sobre ARQT_US — 133 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: ARQT_US ✕ 133 resultados
07/10/2026 ARQT_US — Yahoo Finance
Arcutis Biotherapeutics, Inc. (ARQT) Stock Forecasts

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

06/10/2026 ARQT_US — Quiver Quantitative
Arcutis Biotherapeutics’ ZORYVE Cream 0.15% Wins Marie Claire’s Inaugural Best Prescription Skin Solution Award

ZORYVE cream 0.15% wins Marie Claire's inaugural "Best Prescription Skin Solution" Award for atopic

06/10/2026 ARQT_US — The Manila Times
Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award

Newly created award category highlights innovation in prescription skin treatmentZORYVE cream 0.15% for mild to moderate atopic dermatitis (eczema) in adults and children 6 years of age and older is first medication to win the awardZORYVE is the number one prescribed branded topical therapy across three major inflammatory skin conditions combined - eczema, plaque psoriasis, and seborrheic dermatitis WESTLAKE VILLAGE, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that ZORYVE® (roflumilast) cream 0.15% was presented with the 2026

05/10/2026 ARQT_US — Stock Traders Daily
Trading Systems Reacting to (ARQT) Volatility

Price-action only: Arcutis Biotherapeutics Inc. (ARQT) movements set the tone for institutional models. Trading Systems Reacting to (ARQT) Volatility

03/10/2026 ARQT_US — The Manila Times
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 62,500 restricted stock units (RSUs) of Arcutis common stock to six newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of October 1, 2026, as a material inducement to the new employees in connection with their commencement of employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).

02/10/2026 ARQT_US — The Manila Times
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing...

01/10/2026 ARQT_US — Yahoo Finance
Arcutis Biotherapeutics, Inc. (ARQT) Stock Forecasts

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

01/10/2026 ARQT_US — Yahoo Finance
Arcutis Biotherapeutics, Inc. (ARQT) Stock Forecasts

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Página 3 de 7